United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

Name: United Therapeutics Corp: Is Infosys Ltd. worth buying?
Item: United Therapeutics Corp
Rating: 2.399541625
Author: Trendlyne DVM scores

Mid-range Performer

about

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

307.24 1.90 (0.62%)

26.47% Fall from 52W High

749.9K

XNAS Volume

XNAS 28 Aug, 2025 5:30 PM (EDT)

Medium Financial Strength

50.0 / 100

Mid Valuation

48.3 / 100

Technically Neutral

43.6 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

381

1Yr Price target upside is 24%

12 analysts

United Therapeutics Corp Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

United Therapeutics Corp Live Stock Price Today, Share Analysis and Chart

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on...

26.47% Fall from 52W High

SWOT Analysis

United Therapeutics Corp Live Price Chart